HIV testing: The cornerstone of HIV prevention efforts in the USA

Future Virology

Volumn 6, Issue 11, 2011, Pages 1299-1317

  Heffelfinger, James D ^a   Owen, S Michele ^a   Hendry, R Michael ^a   Lansky, Amy ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

acute HIV infection; HIV diagnostics; HIV prevention; HIV testing; linkage to care; retention in care

Indexed keywords

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MORBIDITY; MORTALITY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; UNITED STATES; VIRUS DETECTION; VIRUS TRANSMISSION;

EID: 80755159099     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.114     Document Type: Review

References (163)

1. Centers for Disease Control and Prevention. HIV Surveillance-United States, 1981-2008. MMWR Morb. Mortal. Wkly Rep. 60(21), 689-693 (2011).
2. Prejean J, Song R, Hernandez A et al. Estimated HIV Incidence in the United States, 2006-2009. PLoS One 6(8), E17502 (2011).
3. Fleming PL, Ward JW, Karon JM, Hanson DL, De Cock KM. Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 12(Suppl. A), S55-S61 (1998).
4. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 13(13), 1687-1695 (1999). (Pubitemid 30015716)
5. Cain LE, Cole SR, Chmiel JS, Margolick JB, Rinaldo CR Jr, Detels R. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. Am. J. Epidemiol. 163(4), 310-315 (2006). (Pubitemid 43238424)
6. Bhaskaran K, Hamouda O, Sannes M et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300(1), 51-59 (2008). (Pubitemid 351920404)
7. Hall HI, Green TA, Wolitski RJ et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J. Acquir. Immune Defic. Syndr. 55(2), 271-276 (2010).
8. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 20(10), 1447-1450 (2006). (Pubitemid 43948252)
9. Lansky A, Brooks JT, DiNenno E, Heffelfinger J, Hall HI, Mermin J. Epidemiology of HIV in the United States. J. Acquir. Immune Defic. Syndr. 55(Suppl. 2), S64-S68 (2010).
10. Centers for Disease Control and Prevention. Vital signs: HIV testing and diagnosis among adults - United States, 2001-2009. MMWR Morb. Mortal. Wkly Rep. 59(47), 1550-1555 (2010).
11. Branson BM, Handsfield HH, Lampe MA et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm. Rep. 55(RR-14), 1-17; quiz CE11-CE14 (2006).
12. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J. Acquir. Immune Defic. Syndr. 40(1), 96-101 (2005). (Pubitemid 41233212)
13. Donnell D, Baeten JM, Kiarie J et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375(9731), 2092-2098 (2010).
14. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin. Infect. Dis. 52(6), 793-800 (2011).
15. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998). (Pubitemid 28135961)
16. Walensky RP, Paltiel AD, Losina E et al. The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 194(1), 11-19 (2006).
17. Detels R, Munoz A, McFarlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 280(17), 1497-1503 (1998). (Pubitemid 28507402)
18. Jones JL, Hanson DL, Dworkin MS et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill. Summ. 48(2), 1-22 (1999).
19. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352(9142), 1725-1730 (1998). (Pubitemid 28534954)
20. Miller V, Mocroft A, Reiss P et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann. Intern. Med. 130(7), 570-577 (1999). (Pubitemid 29169384)
21. Dore GJ, Li Y, McDonald A, Ree H, Kaldor JM. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J. Acquir. Immune Defic. Syndr. 29(4), 388-395 (2002). (Pubitemid 34288893)
22. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J. Acquir. Immune Defic. Syndr. 39(4), 446-453 (2005). (Pubitemid 41003791)
23. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N. Engl. J. Med. 364(20), 1943-1954 (2011).
24. Powers KA, Ghani AC, Miller WC et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 378(9787), 256-268 (2011).
25. Branson BM. The future of HIV testing. J. Acquir. Immune Defic. Syndr. 55(Suppl. 2), S102-S105 (2010).
26. Morrison CS, Demers K, Kwok C et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS 24(4), 573-582 (2010).
27. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324(14), 961-964 (1991).
28. Pilcher CD, Joaki G, Hoffman IF et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 21(13), 1723-1730 (2007). (Pubitemid 47237559)
29. Koopman JS, Simon CP. Response to Rapatski BL, Suppe F, Yorke JA. HIV epidemics driven by late disease stage transmission. J. Acquir. Immune Defic. Syndr. 41(5), 677 (2006).
30. Wawer MJ, Gray RH, Sewankambo NK et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191(9), 1403-1409 (2005). (Pubitemid 40563350)
31. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J. Infect. Dis. 198(5), 687-693 (2008).
32. Brenner BG, Roger M, Routy JP et al. High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 195(7), 951-959 (2007). (Pubitemid 46452099)
33. Centers for Disease Control and Prevention. Prevalence and awareness of HIV infection among men who have sex with men-21 cities, United States, 2008. MMWR Morb. Mortal. Wkly Rep. 59(37), 1201-1207 (2010).
34. Centers for Disease Control and Prevention. HIV testing among men who have sex with men - 21 cities, United States, 2008. MMWR Morb. Mortal. Wkly Rep. 60(21), 694-699 (2011).
35. Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342(13), 921-929 (2000). (Pubitemid 30177052)
36. Tovanabutra S, Robison V, Wongtrakul J et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J. Acquir. Immune Defic. Syndr. 29(3), 275-283 (2002). (Pubitemid 34208536)
37. Baeten JM, Kahle E, Lingappa JR et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci. Transl. Med. 3(77), 77RA29 (2011).
38. Montaner JS, Hogg R, Wood E et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368(9534), 531-536 (2006). (Pubitemid 44142776)
39. Venkatesh KK, Lurie MN, Mayer KH. How HIV treatment could result in effective prevention. Future Virol. 5(4), 405-415 (2010).
40. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J. Acquir. Immune Defic. Syndr. 41(5), 632-641 (2006).
41. Garnett GP, Gazzard B. Risk of HIV transmission in discordant couples. Lancet 372(9635), 270-271 (2008). (Pubitemid 352020422)
42. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. (2011).
43. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, 373(9657), 48-57 (2009).
44. Walensky RP, Paltiel AD, Losina E et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin. Infect. Dis. 51(4), 392-400 (2010).
45. Centers for Disease Control and Prevention. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb. Mortal. Wkly Rep. 38(Suppl. 7), 1-7 (1989).
46. Fiebig EW, Wright DJ, Rawal BD et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17(13), 1871-1879 (2003). (Pubitemid 37070272)
47. Owen SM, Yang C, Spira T et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J. Clin. Microbiol. 46(5), 1588-1595 (2008). (Pubitemid 351657199)
48. Parry JV, Mortimer PP, Perry KR, Pillay D, Zuckerman M. Towards error-free HIV diagnosis: guidelines on laboratory practice. Commun. Dis. Public Health 6(4), 334-350 (2003).
49. Weber B, Gurtler L, Thorstensson R et al. Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity. J. Clin. Microbiol. 40(6), 1938-1946 (2002). (Pubitemid 34596366)
50. Ly TD, Martin L, Daghfal D et al. Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J. Clin. Microbiol. 39(9), 3122-3128 (2001). (Pubitemid 32830303)
51. Ly TD, Laperche S, Brennan C et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J. Virol. Methods 122(2), 185-194 (2004). (Pubitemid 39470190)
52. Weber B. Screening of HIV infection: role of molecular and immunological assays. Expert Rev. Mol. Diagn. 6(3), 399-411 (2006). (Pubitemid 44174344)
53. Chavez P, Wesolowski L, Patel P, Delaney K, Owen SM. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab combo assay. J. Clin. Virol. (2011) (In Press).
54. Delaney KP, Branson BM, Uniyal A et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin. Infect. Dis. 52(2), 257-263 (2011).
55. O'Conell RJ, Peel SA. Multispot HIV-1/ HIV-2 Rapid Test: advantages over other rapid HIV tests. Expert Rev. Mol. Diagn. 7(5), 499-505 (2007).
56. Pilcher CD, Christopoulos KA, Golden M. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV. J. Infect. Dis. 201(Suppl. 1), S7-S15 (2010).
57. Centers for Disease Control and Prevention. Notice to readers: protocols for confirmation of reactive rapid HIV tests. MMWR Morb. Mortal. Wkly Rep. 53(10), 221-222 (2004).
58. Greensides DR, Berkelman R, Lansky A, Sullivan PS. Alternative HIV testing methods among populations at high risk for HIV infection. Public Health Rep. 118(6), 531-539 (2003). (Pubitemid 37428871)
59. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am. J. Med. 102(5B), 117-124; discussion 125-116 (1997).
60. Lindback S, Karlsson AC, Mittler J et al. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 14(15), 2283-2291 (2000).
61. Patel P, Mackellar D, Simmons P et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern. Med. 170(1), 66-74 (2010).
62. Facente SN, Pilcher CD, Hartogensis WE et al. Performance of risk-based criteria for targeting acute HIV screening in San Francisco. PLoS One 6(7), E21813 (2011).
63. Pilcher CD, Fiscus SA, Nguyen TQ et al. Detection of acute infections during HIV testing in North Carolina. N. Engl. J. Med. 352(18), 1873-1883 (2005). (Pubitemid 40627813)
64. Truong HM, Grant RM, McFarland W et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17), 2193-2197 (2006). (Pubitemid 44684710)
65. Priddy FH, Pilcher CD, Moore RH et al. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J. Acquir. Immune Defic. Syndr. 44(2), 196-202 (2007). (Pubitemid 46292223)
66. Stekler JD, Swenson PD, Coombs RW et al. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin. Infect. Dis. 49(3), 444-453 (2009).
67. Clark JL, Segura ER, Montano SM et al. Routine laboratory screening for acute and recent HIV infection in Lima, Peru. Sex. Transm. Infect. 86(7), 545-547 (2010).
68. Pandori MW, Hackett J Jr, Louie B et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J. Clin. Microbiol. 47(8), 2639-2642 (2009).
69. O'Brien TR, George JR, Holmberg SD. Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. JAMA 267(20), 2775-2779 (1992).
70. Centers for Disease Control and Prevention. HIV-2 Infection Surveillance-United States, 1987-2009. MMWR Morb. Mortal. Wkly Rep. 60, 985-988 (2011).
71. Matheron S, Pueyo S, Damond F et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 17(18), 2593-2601 (2003). (Pubitemid 38402337)
72. Marlink R, Kanki P, Thior I et al. Reduced rate of disease development after HIV-2 infection as compared with HIV-1. Science 265(5178), 1587-1590 (1994). (Pubitemid 24308975)
73. Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob. Agents Chemother. 53(9), 3611-3619 (2009).
74. Torian LV, Eavey JJ, Punsalang AP et al. HIV type 2 in New York City, 2000-2008. Clin. Infect. Dis. 51(11), 1334-1342 (2010).
75. Nasrullah M, Ethridge SF, Delaney KP et al. Comparison of alternative interpretive criteria for the HIV-1 western blot and results of the Multispot HIV-1/HIV-2 rapid test for classifying HIV-1 and HIV-2 infections. J. Clin. Virol. (2011) (In Press).
76. Branson B. Conference wrap-up: unified laboratory algorithm. Presented at: 2010 HIV Diagnostics Conference. Orlando, FL, USA, 24-26 March 2010.
77. Pandori MW, Branson BM. 2010 HIV Diagnostics Conference. Expert Rev. Anti. Infect. Ther. 8(6), 631-633 (2010).
78. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, SM Owen. Evaluation of alternative diagnostic algorithms using specimens from early and established HIV infections in the United States. J. Clin. Virol. (2011) (In Press).
79. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years - United States 2008 MMWR Recomm. Rep. 57 RR-10 1-12 2008
80. Centers for Disease Control and Prevention. Characteristics Associated with HIV Infection Among Heterosexuals in Urban Areas with High AIDS Prevalence-24 Cities, United States, 2006-2007. MMWR Morb. Mortal. Wkly Rep. 60, 1045-1049 (2011).
81. Braunstein SL, Nash D, Kim AA et al. Dual Testing algorithm of BED-CEIA and AxSYM avidity index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers. PLoS One 6(4), E18402 (2011).
82. McDougal JS, Pilcher CD, Parekh BS et al. Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries. AIDS 19 (Suppl. ), S25-S30 (2005).
83. Parekh BS, Hu DJ, Vanichseni S et al. Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res. Hum. Retroviruses. 17(5), 453-458 (2001). (Pubitemid 32506937)
84. Rutherford GW, Schwarcz SK, McFarland W. Surveillance for incident HIV infection: new technology and new opportunities. J. Acquir. Immune Defic. Syndr. 25(Suppl. 2), S115-S119 (2000). (Pubitemid 32055561)
85. Janssen RS, Satten GA, Stramer SL et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 280(1), 42-48 (1998). (Pubitemid 28414995)
86. Parekh BS, Kennedy MS, Dobbs T et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res. Hum. Retroviruses 18(4), 295-307 (2002). (Pubitemid 34253148)
87. Suligoi B, Massi M, Galli C et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J. Acquir. Immune Defic. Syndr. 32(4), 424-428 (2003). (Pubitemid 36363157)
88. McDougal JS, Parekh BS, Peterson ML et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res. Hum. Retroviruses, 22(10), 945-952 (2006). (Pubitemid 46100678)
89. Barnighausen T, McWalter TA, Rosner Z, Newell ML, Welte A. HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis. Epidemiology 21(5), 685-697 (2010).
90. Janssen RS, Holtgrave DR, Valdiserri RO, Shepherd M, Gayle HD, De Cock KM. The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals. Am. J. Public Health 91(7), 1019-1024 (2001). (Pubitemid 32574820)
91. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm. Rep. 50(RR-19), 1-57; quiz CE51-19a51-CE56- 19a51 (2001).
92. Centers for Disease Control and Prevention. Advancing HIV Prevenion: new strategies for a changing epidemic - United States, 2003. Morb. Mortal. Wkly Rep. 52(15), 329-332 (2003).
93. Heffelfinger JD, Sullivan PS, Branson BM et al. Advancing HIV prevention demonstration projects: new strategies for a changing epidemic. Public Health Rep. 123(Suppl. 3), 5-15 (2008).
94. Centers for Disease Control and Prevention. Results of Expanded HIV Testing Initiative - 25 Jurisdictions, 2007-2010. MMWR Morb. Mortal. Wkly Rep. 60(24), 805-810 (2011).
95. Daskalakis D. HIV diagnostic testing: Evolving technology and testing strategies. Topics Antiviral. Med. 19(1), 18-22 (2011).
96. Greenberg AE, Hader SL, Masur H, Young AT, Skillicorn J, Dieffenbach CW. Fighting HIV/AIDSin Washington, D.C. Health Aff. (Millwood), 28(6), 1677-1687 (2009).
97. Centers for Disease Control and Prevention. Expanded HIV testing and trends in diagnoses of HIV infection - District of Columbia, 2004-2008. MMWR Morb. Mortal. Wkly Rep. 59(24), 737-741 (2010).
98. Maxwell CJ, Sitapati AM, Abdus-Salaam SS et al. A model for routine hospital-wide HIV screening: lessons learned and public health implications. J. Natl Med. Assoc. 102(12), 1165-1172 (2011).
99. Goggin MA, Davidson AJ, Cantril SV, O'Keefe LK, Douglas JM. The extent of undiagnosed HIV infection among emergency department patients: results of a blinded seroprevalence survey and a pilot HIV testing program. J. Emerg. Med. 19(1), 13-19 (2000). (Pubitemid 30345567)
100. Kelen GD, Hexter DA, Hansen KN et al. Feasibility of an emergency department-based, risk-targeted voluntary HIV screening program. Ann. Emerg. Med. 27(6), 687-692 (1996). (Pubitemid 26180872)
101. Kelen GD, Shahan JB, Quinn TC. Emergency department-based HIV screening and counseling: experience with rapid and standard serologic testing. Ann. Emerg. Med. 33(2), 147-155 (1999). (Pubitemid 29180077)
102. Centers for Disease Control and Prevention. Routinely recommended HIV testing at an urban urgent-care clinic - Atlanta, Georgia, 2000. MMWR Morb. Mortal. Wkly Rep. 50(25), 538-541 (2001).
103. Torres GW, Heffelfinger JD, Pollack HA, Barrera SG, Rothman RE. HIV screening programs in US emergency departments: a cross-site comparison of structure, process, and outcomes. Ann. Emerg. Med. 58(Suppl. 1), S104-S113 (2011).
104. Lyons MS, Lindsell CJ, Haukoos JS et al. Nomenclature and definitions for emergency department human immunodeficiency virus (HIV) testing: report from the 2007 conference of the National Emergency Department HIV Testing Consortium. Acad. Emerg. Med. 16(2), 168-177 (2009).
105. Kecojevic A, Lindsell CJ, Lyons MS et al. Public health and clinical impact of increasing emergency department-based HIV testing: perspectives from the 2007 conference of the National Emergency Department HIV Testing Consortium. Ann. Emerg. Med. 58(Suppl. 1), S151-S159 E151 (2011).
106. Haukoos JS, Hopkins E, Conroy AA et al. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA 304(3), 284-292 (2010).
107. White DA, Scribner AN, Vahidnia F et al. HIV screening in an urban emergency department: comparison of screening using an opt-in versus an opt-out approach. Ann. Emerg. Med. 58(Suppl. 1), S89-S95 (2011).
108. Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS 24(17), 2665-2678 (2010).
109. Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch. Intern. Med. 168(11), 1181-1187 (2008). (Pubitemid 351831401)
110. Delaney K, Knoble T, J. R et al. Using a rapid HIV testing algorithm to improve the accuracy of HIV testing, receipt of test results, and linkage to care: Results of a demonstration project in 2 US cities. Presented at: 18th Conference on Retroviruses and Opportunistic Diseases. Boston, MA, USA, 27 February-2 March 2011.
111. Hutchinson AB, Branson BM, Kim A, Farnham PG. A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status. AIDS 20(12), 1597-1604 (2006). (Pubitemid 44162401)
112. Kassler WJ, Dillon BA, Haley C, Jones WK, Goldman A. On-site, rapid HIV testing with same-day results and counseling. AIDS 11(8), 1045-1051 (1997). (Pubitemid 27259528)
113. Kendrick SR, Kroc KA, Withum D, Rydman RJ, Branson BM, Weinstein RA. Outcomes of offering rapid point-of-care HIV testing in a sexually transmitted disease clinic. J. Acquir. Immune Defic. Syndr. 38(2), 142-146 (2005). (Pubitemid 40189320)
114. Lyss SB, Branson BM, Kroc KA, Couture EF, Newman DR, Weinstein RA. Detecting unsuspected HIV infection with a rapid whole-blood HIV test in an urban emergency department. J. Acquir. Immune Defic. Syndr. 44(4), 435-442 (2007). (Pubitemid 46555379)
115. Liang TS, Erbelding E, Jacob CA et al. Rapid HIV testing of clients of a mobile STD/HIV clinic. AIDS Patient Care STDS 19(4), 253-257 (2005). (Pubitemid 40616936)
116. Gardner LI, Metsch LR, Anderson- Mahoney P et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 19(4), 423-431 (2005). (Pubitemid 40446189)
117. Craw J, Gardner L, Rossman A et al. Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model. BMC Health Serv. Res. 10, 246 (2010).
118. Giordano TP, Gifford AL, White AC Jr et al. Retention in care: a challenge to survival with HIV infection. Clin. Infect. Dis. 44(11), 1493-1499 (2007). (Pubitemid 46801595)
119. Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin. Infect. Dis. 52(Suppl. 2), S238-S246 (2011).
120. Aberg JA, Kaplan JE, Libman H et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 49(5), 651-681 (2009).
121. Buscher AL, Giordano TP. Gaps in knowledge in caring for HIV survivors long-term. JAMA 304(3), 340-341 (2010).
122. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126(12), 946-954 (1997). (Pubitemid 27255797)
123. Torian LV, Wiewel EW. Continuity of HIV-related medical care, New York City, 2005-2009: Do patients who initiate care stay in care? AIDS Patient Care STDS, 25(2), 79-88 (2011).
124. Prabhu VS, Farnham PG, Hutchinson AB et al. Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One 6(5), E19936 (2011).
125. Paltiel AD, Weinstein MC, Kimmel AD et al. Expanded screening for HIV in the United States - an analysis of cost- effectiveness. N. Engl. J. Med. 352(6), 586-595 (2005). (Pubitemid 40204671)
126. Sanders GD, Bayoumi AM, Sundaram V et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N. Engl. J. Med, 352(6), 570-585 (2005). (Pubitemid 40204670)
127. Walensky RP, Losina E, Malatesta L et al. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am. J. Public Health, 95(1), 71-73 (2005). (Pubitemid 40075883)
128. Silva A, Glick NR, Lyss SB et al. Implementing an HIV and sexually transmitted disease screening program in an emergency department. Ann. Emerg. Med. 49(5), 564-572 (2007). (Pubitemid 46628721)
129. Mehta SD, Hall J, Greenwald JL, Cranston K, Skolnik PR. Patient risks, outcomes, and costs of voluntary HIV testing at five testing sites within a medical center. Public Health Rep. 123(5), 608-617 (2008).
130. Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep. 123(Suppl. 3), 51-62 (2008).
131. Shrestha RK, Clark HA, Sansom SL et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep, 123(Suppl. 3), 94-100 (2008).
132. Varghese B, Peterman TA. Cost-effectiveness of HIV counseling and testing in US prisons. J. Urban Health 78(2), 304-312 (2001). (Pubitemid 32545533)
133. Golden MR, Gift TL, Brewer DD et al. Peer referral for HIV case-finding among men who have sex with men. AIDS 20(15), 1961-1968 (2006). (Pubitemid 44427614)
134. Shrestha RK, Sansom SL, Richardson- Moore A et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 states- advancing HIV Prevention Demonstration Project, 2003-2006. Sex. Transm. Dis. 36(Suppl. 2), S5-S8 (2009).
135. Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med. Decis. Making, 25(3), 321-329 (2005). (Pubitemid 40696281)
136. Schackman BR, Gebo KA, Walensky RP et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med. Care 44(11), 990-997 (2006). (Pubitemid 44674030)
137. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann. Intern. Med. 153(12), 778-789 (2010).
138. Mimiaga MJ, Johnson CV, Reisner SL, Vanderwarker R, Mayer KH. Barriers to routine HIV testing among Massachusetts community health center personnel. Public Health Rep. 126(5), 643-652 (2011).
139. Neff S, Goldschmidt R. Centers for Disease Control and Prevention 2006 human immunodeficiency virus testing recommendations and state testing laws. JAMA 305(17), 1767-1768 (2011).
140. Ehrenkranz PD, Pagan JA, Begier EM, Linas BP, Madison K, Armstrong K. Written informed-consent statutes and HIV testing. Am. J. Prev. Med. 37(1), 57-63 (2009).
141. Zetola NM, Grijalva CG, Gertler S et al. Simplifying consent for HIV testing is associated with an increase in HIV testing and case detection in highest risk groups, San Francisco January 2003-June 2007. PLoS One 3(7), E2591 (2008).
142. Wing C. Effects of written informed consent requirements on HIV testing rates: evidence from a natural experiment. Am. J. Public Health, 99(6), 1087-1092 (2009).
143. Halpern SD, Metkus TS, Fuchs BD et al. Nonconsented human immunodeficiency virus testing among critically ill patients: intensivists' practices and the influence of state laws. Arch Intern. Med. 167(21), 2323-2328 (2007). (Pubitemid 350179527)
144. Neff S, Goldschmidt RH. State human immunodeficiency virus testing laws. Arch Intern. Med. 168(15), 1717-1718 (2008).
145. Meng YY, Coffman JM, Ripps JC, Lee C, Kominski GF. Financial impact of California's new law to increase HIV screening by mandating insurance coverage. AIDS Care 23(2), 206-212 (2011).
146. Burke RC, Sepkowitz KA, Bernstein KT et al. Why don't physicians test for HIV? A review of the US literature. AIDS 21(12), 1617-1624 (2007). (Pubitemid 47075483)
147. Rodnick JE. The CDC and USPSTF recommendations for HIV testing. Am. Fam. Physician 76(10), 1456, 1459 (2007). (Pubitemid 350127897)
148. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 367(9525), 1870-1872 (2006). (Pubitemid 43833194)
149. Merchant RC, Waxman MJ. HIV screening in health care settings: some progress, even more questions. JAMA 304(3), 348-349 (2010).
150. Kilmartin P. Development of the VITROS HIV combo assay. Presented at: 2010 HIV Diagnostics Conference. Orlando, FL, USA, 24-26 March 2010.
151. Curtis KA, Rudolph DL, Owen SM. Rapid detection of HIV-1 by
152. Tang W, Chow WH, Li Y, Kong H, Tang YW, Lemieux B. Nucleic acid assay system for tier II laboratories and moderately complex clinics to detect HIV in low-resource settings. J. Infect. Dis. 201(Suppl. 1), S46-S51 (2010).
153. Lee HH, Dineva MA, Chua YL, Ritchie AV, Ushiro-Lumb I, Wisniewski CA. Simple amplification-based assay: a nucleic acid-based point-of-care platform for HIV-1 testing. J. Infect. Dis. 201(Suppl. 1), S65-S72 (2010).
154. Tanriverdi S, Chen L, Chen S. A rapid and automated sample-to-result HIV load test for near-patient application. J. Infect. Dis. 201(Suppl. 1), S52-S58 (2010).
155. Pau C-P, Wells SK, Owen SM, Granade TC. Development of a simple, rapid and inexpensive method for the qualitative detection of HIV-1 RNA. Presented at: 2010 HIV Diagnostics Conference. Orlando, FL, USA, 24-26 March 2010.
156. Mazzola LT, Arsham AM, Pederson AM, Bhatia R, Stern D, Laser DJ. Innovative point-of-care HIV viral load detection in RLS. Presented at: 2010 HIV Diagnostics Conference. Orlando, FL, USA, 24-26 March 2010.
157. Wei X, Liu X, Dobbs T et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res. Hum. Retroviruses 26(1), 61-71 (2010).
158. Masciotra S, Dobbs T, Candal D et al. Antibody avidity-based assay for identifying recent HIV-1 infections based on Genetic SystemsTM 1/2 Plus O EIA. Presented at: Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 3-5 March 2010.
159. Keating SM, Hanson D, Lebedeva L et al. Optimization and calibration of less sensitive and avidity modified protocols for the Vitros immunodiagnostic products anti-HIV-1+2 assay for detection of early HIV infections. Presented at: 2010 HIV Diagnostics Conference. Orlando, FL, USA, 24-26 March 2010.
160. Laeyendecker O, Oliver A, Astemborski J et al. Improved precision of cross-sectional HIV incidence testing using a multi-assay algorithm that includes BED and an avidity assay with modified assay cut-offs. Presented at: Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 5-8 March 2010.
161. Curtis KA, Kennedy MS, Charurat M et al. Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. AIDS Res. Hum. Retroviruses doi:10.1089/ aid.2011.0037 (2011) (Epub ahead of print).
162. Park SY, Love TM, Nelson J, Thurston SW, Perelson AS, Lee HY. Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS 25(16), F13-F19 (2011).
163. Incidence Assay Critical Path Working Group. More and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS Med. 8(6), E1001045 (2011).